Clinic
Gundersen Lutheran Medical Center INC
Gundersen Lutheran Medical Center INC was paid $74.27M by Medicaid between Jan 2018 and Dec 2024, across 737 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 15% of everything it billed.
33Billing provider infoGUNDERSEN LUTHERAN MEDICAL CENTER INC
LA CROSSE, WI 54601
LA CROSSE, WI 54601
33aNPI1376593442assigned 05/11/2006
33bProvider typeEnd-Stage Renal Disease (ESRD) Treatment Clinic/Center
28Total paid$74.27M
24GClaims2,985,350
24DCodes billed737
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other End-Stage Renal Disease (ESRD) Treatment Clinic/Center providers in Wisconsin
Rank by total paid#1 of 120
Median peer was paid$662K
This provider vs. median112×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ADANK, KARI controls 16+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 377,608 | $9.12M | |
| 2019 | 376,209 | $9.83M | |
| 2020 | 340,530 | $8.65M | |
| 2021 | 479,317 | $11.46M | |
| 2022 | 497,506 | $11.73M | |
| 2023 | 505,122 | $12.61M | |
| 2024incomplete | 409,058 | $10.87M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 15% | 198,682 | 172,660 | $11.28M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 13% | 204,326 | 179,787 | $9.86M |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 4.7% | 47,117 | 39,916 | $3.47M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3.5% | 108,246 | 82,632 | $2.58M |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.8% | 20,879 | 11,903 | $2.08M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.7% | 38,770 | 33,120 | $2.03M |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | 2.1% | 30,158 | 26,632 | $1.56M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.0% | 21,178 | 17,774 | $1.50M |
| H0018 | Behavioral health; short-term residential (non-hospital residential treatment program), without room and board, per diem | 1.8% | 7,672 | 422 | $1.33M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 1.8% | 26,476 | 23,244 | $1.31M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 1.8% | 24,282 | 7,170 | $1.31M |
| 80051 | 1.4% | 51,830 | 38,091 | $1.04M |
725 more codes
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.3% | 15,225 | $989K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.2% | 20,818 | $898K |
| 99283 | Emergency room visit (moderate) | 1.2% | 14,602 | $868K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.1% | 43,078 | $808K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 21,072 | $666K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 6,905 | $606K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 2,819 | $577K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 13,020 | $563K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 10,535 | $562K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 6,503 | $511K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 15,135 | $492K |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 9,670 | $480K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 3,904 | $447K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 8,054 | $437K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 10,107 | $419K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 7,326 | $417K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 9,695 | $406K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 32,391 | $403K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 15,843 | $401K |
| C9257 | Injection, bevacizumab, 0.25 mg | <1% | 4,333 | $398K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 13,638 | $388K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 9,337 | $388K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 7,709 | $387K |
| 90686 | <1% | 13,371 | $382K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 51,095 | $364K |
| 82565 | <1% | 71,579 | $363K | |
| 80061 | Lipid panel | <1% | 24,954 | $353K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 6,933 | $331K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 10,841 | $319K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 18,724 | $306K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 1,607 | $297K |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 4,928 | $294K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 8,790 | $270K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 6,443 | $267K |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 5,585 | $261K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 25,674 | $258K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 4,281 | $253K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 2,628 | $247K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 7,523 | $246K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 1,234 | $240K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 19,341 | $239K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 479 | $238K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 3,105 | $230K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 42,707 | $222K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 2,978 | $219K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,250 | $213K |
| G0378 | Hospital observation service, per hour | <1% | 7,784 | $212K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 6,586 | $211K |
| 82728 | <1% | 16,785 | $211K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 36,680 | $208K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 4,556 | $206K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,112 | $188K |
| 92015 | Determination of refractive state | <1% | 21,090 | $187K |
| 20610 | <1% | 4,232 | $186K | |
| 59025 | Fetal non-stress test | <1% | 2,756 | $184K |
| 90670 | <1% | 4,178 | $179K | |
| 96040 | <1% | 1,824 | $171K | |
| 62323 | <1% | 1,155 | $170K | |
| 96415 | <1% | 1,860 | $167K | |
| 82247 | <1% | 23,718 | $165K | |
| J0178 | Injection, aflibercept, 1 mg | <1% | 1,044 | $164K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 2,845 | $162K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 243 | $159K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 6,811 | $159K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 5,255 | $156K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 3,664 | $154K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 3,932 | $150K |
| 92567 | <1% | 3,906 | $148K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 6,916 | $146K |
| 85610 | <1% | 14,440 | $143K | |
| 82962 | <1% | 22,653 | $140K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 679 | $138K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 394 | $138K |
| 82040 | <1% | 9,007 | $137K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 13,143 | $135K |
| 84460 | <1% | 36,420 | $132K | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 3,204 | $131K |
| 90651 | <1% | 1,716 | $130K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 2,637 | $128K |
| 82947 | <1% | 41,235 | $126K | |
| 90837 | Psychotherapy session, about an hour | <1% | 2,395 | $124K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 825 | $122K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 2,435 | $121K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,980 | $121K |
| 93325 | <1% | 4,029 | $115K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 3,997 | $112K |
| H2012 | Behavioral health day treatment, per hour | <1% | 5,333 | $109K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,335 | $108K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 27,811 | $108K |
| 86900 | <1% | 4,964 | $107K | |
| 97162 | <1% | 4,166 | $106K | |
| 90633 | <1% | 2,233 | $105K | |
| 92340 | Fitting of spectacles, except for aphakia; monofocal | <1% | 5,706 | $105K |
| 11721 | <1% | 5,297 | $105K | |
| 96367 | <1% | 1,919 | $100K | |
| 81001 | <1% | 18,764 | $99K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 2,251 | $98K |
| 84450 | <1% | 24,531 | $97K | |
| 81025 | <1% | 9,720 | $96K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 489 | $95K |
| 87210 | <1% | 6,065 | $95K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,690 | $92K |
| 85027 | <1% | 19,298 | $92K | |
| 87081 | <1% | 7,713 | $90K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 6,241 | $90K |
| J2315 | Injection, naltrexone, depot form, 1 mg | <1% | 606 | $89K |
| 82043 | <1% | 8,700 | $87K | |
| 90715 | <1% | 3,466 | $85K | |
| 84439 | <1% | 7,786 | $84K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 5,265 | $84K |
| 83970 | <1% | 3,784 | $82K | |
| 86703 | <1% | 6,497 | $82K | |
| 64615 | <1% | 925 | $82K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,152 | $81K |
| 81003 | <1% | 11,298 | $81K | |
| 96101 | <1% | 309 | $79K | |
| 49083 | <1% | 528 | $78K | |
| 84520 | <1% | 33,011 | $77K | |
| 97597 | <1% | 2,272 | $76K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 1,438 | $73K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,068 | $71K |
| 97161 | <1% | 2,268 | $70K | |
| 86803 | <1% | 6,376 | $68K | |
| 97165 | <1% | 2,337 | $68K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 3,831 | $66K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,767 | $65K |
| 83655 | <1% | 4,310 | $64K | |
| 87077 | <1% | 6,198 | $63K | |
| 84075 | <1% | 18,351 | $63K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,412 | $62K |
| 96130 | <1% | 576 | $62K | |
| 93320 | <1% | 865 | $61K | |
| 94010 | <1% | 3,947 | $60K | |
| 82310 | <1% | 14,267 | $58K | |
| 98940 | <1% | 4,852 | $58K | |
| 76642 | <1% | 1,802 | $57K | |
| 82607 | <1% | 5,608 | $57K | |
| 97166 | <1% | 1,885 | $56K | |
| 82805 | <1% | 2,377 | $56K | |
| 3008F | <1% | 6,673 | $55K | |
| 95886 | <1% | 962 | $55K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,216 | $54K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 3,772 | $54K |
| 83735 | <1% | 12,179 | $53K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 914 | $53K |
| 84484 | <1% | 7,412 | $53K | |
| 83690 | <1% | 10,942 | $53K | |
| 92523 | <1% | 662 | $53K | |
| 51705 | <1% | 951 | $52K | |
| 83550 | <1% | 9,293 | $52K | |
| 94060 | <1% | 2,264 | $51K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 10,689 | $51K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 982 | $49K |
| 90688 | <1% | 1,072 | $48K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 3,715 | $48K |
| 76770 | <1% | 737 | $48K | |
| 91320 | <1% | 972 | $48K | |
| 87340 | <1% | 6,457 | $47K | |
| 87070 | <1% | 3,204 | $47K | |
| 86780 | <1% | 5,196 | $45K | |
| 99460 | <1% | 513 | $45K | |
| 84132 | <1% | 13,302 | $44K | |
| 84702 | <1% | 2,267 | $44K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,304 | $44K |
| 0002A | <1% | 1,355 | $44K | |
| 83516 | <1% | 3,710 | $44K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 861 | $43K |
| 93971 | <1% | 1,702 | $43K | |
| 80164 | <1% | 1,339 | $43K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 1,232 | $43K |
| 86140 | <1% | 8,286 | $43K | |
| 87505 | <1% | 504 | $42K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,312 | $41K |
| 90680 | <1% | 2,452 | $41K | |
| 83880 | <1% | 2,472 | $41K | |
| 82784 | <1% | 3,296 | $41K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 317 | $40K |
| 93017 | <1% | 939 | $40K | |
| 96116 | <1% | 516 | $39K | |
| 83540 | <1% | 9,342 | $39K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 852 | $39K |
| 0001A | <1% | 1,341 | $39K | |
| 87186 | <1% | 7,103 | $39K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 1,214 | $39K |
| 73630 | <1% | 6,342 | $38K | |
| 90685 | <1% | 1,022 | $37K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 600 | $37K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 1,463 | $36K |
| 86850 | <1% | 7,487 | $36K | |
| 89051 | <1% | 1,092 | $35K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,491 | $35K |
| 83605 | <1% | 5,558 | $35K | |
| 86617 | <1% | 1,387 | $34K | |
| 95874 | <1% | 853 | $34K | |
| 71250 | <1% | 1,332 | $34K | |
| V2020 | Frames, purchases | <1% | 1,061 | $33K |
| 84403 | <1% | 1,510 | $33K | |
| 90698 | <1% | 2,861 | $33K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 444 | $33K |
| 71045 | Radiologic examination, chest; single view | <1% | 10,363 | $32K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 16,380 | $32K |
| 73610 | <1% | 4,849 | $31K | |
| 86480 | <1% | 742 | $31K | |
| 87040 | <1% | 5,221 | $31K | |
| 93296 | <1% | 1,532 | $31K | |
| 86235 | <1% | 398 | $31K | |
| 92587 | <1% | 545 | $31K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 1,598 | $30K |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 685 | $30K |
| 90734 | <1% | 1,036 | $30K | |
| 85018 | <1% | 10,014 | $30K | |
| 97803 | <1% | 2,930 | $29K | |
| 84153 | <1% | 1,949 | $29K | |
| 97116 | <1% | 2,306 | $29K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 684 | $29K |
| 92557 | <1% | 1,253 | $27K | |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 350 | $27K |
| 12001 | <1% | 268 | $26K | |
| 93308 | <1% | 329 | $26K | |
| 64643 | <1% | 158 | $26K | |
| 86762 | <1% | 1,935 | $26K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 83 | $25K |
| 84145 | <1% | 1,874 | $25K | |
| 82570 | <1% | 3,196 | $25K | |
| 80305 | <1% | 1,561 | $24K | |
| 92134 | <1% | 5,258 | $24K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 844 | $24K |
| 84100 | <1% | 8,290 | $24K | |
| 64642 | <1% | 273 | $24K | |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or qualified healthcare professional, with or without direct patient contact (list separately in addition to cpt codes 99205, 99215, 99483 for office or other outpatient evaluation and management services) (do not report g2212 on the same date of service as 99358, 99359, 99415, 99416). (do not report g2212 for any time unit less than 15 minutes) | <1% | 4,301 | $23K |
| 86704 | <1% | 2,465 | $23K | |
| J1944 | Injection, aripiprazole lauroxil, (aristada), 1 mg | <1% | 160 | $23K |
| 82950 | <1% | 1,927 | $23K | |
| 88307 | <1% | 1,161 | $23K | |
| 73562 | <1% | 3,873 | $22K | |
| 73502 | <1% | 3,253 | $22K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 298 | $22K |
| 36415 | Collection of venous blood by venipuncture | <1% | 17,629 | $21K |
| 17110 | <1% | 347 | $21K | |
| 74018 | <1% | 3,535 | $21K | |
| 99205 | Prolong outpt/office vis | <1% | 207 | $21K |
| 84295 | <1% | 7,397 | $21K | |
| 87522 | Neg quan hep c or qual rna | <1% | 570 | $20K |
| 77066 | Tomosynthesis, mammo | <1% | 821 | $20K |
| 86706 | <1% | 2,558 | $20K | |
| 77065 | Tomosynthesis, mammo | <1% | 823 | $20K |
| 82465 | <1% | 1,424 | $19K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 2,289 | $19K |
| 87631 | <1% | 176 | $19K | |
| 82274 | <1% | 1,393 | $18K | |
| J1610 | Injection, glucagon hydrochloride, per 1 mg | <1% | 881 | $18K |
| 80306 | <1% | 1,128 | $18K | |
| 85379 | <1% | 2,487 | $18K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 291 | $17K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 928 | $17K |
| 90696 | <1% | 607 | $17K | |
| 95819 | <1% | 181 | $16K | |
| 93321 | <1% | 235 | $16K | |
| 97163 | <1% | 709 | $16K | |
| 86364 | <1% | 1,922 | $16K | |
| 90716 | <1% | 896 | $16K | |
| 82105 | <1% | 319 | $16K | |
| 10060 | <1% | 178 | $15K | |
| 77336 | <1% | 273 | $15K | |
| 73030 | <1% | 3,930 | $15K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 344 | $15K |
| 90732 | <1% | 1,090 | $15K | |
| 72100 | <1% | 2,728 | $14K | |
| 73110 | <1% | 2,105 | $14K | |
| 90648 | <1% | 268 | $14K | |
| 86003 | <1% | 1,264 | $14K | |
| 86708 | <1% | 1,434 | $14K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 20,636 | $14K |
| 95806 | <1% | 253 | $14K | |
| 0004A | <1% | 906 | $14K | |
| 52000 | <1% | 80 | $13K | |
| 82550 | <1% | 2,197 | $13K | |
| 96368 | <1% | 262 | $13K | |
| 76942 | <1% | 2,069 | $13K | |
| 70498 | <1% | 197 | $13K | |
| 70496 | <1% | 191 | $13K | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 12,592 | $13K |
| 99479 | Subsequent intensive care, per day, very low birth weight infant | <1% | 148 | $12K |
| 85045 | <1% | 4,204 | $12K | |
| 85652 | <1% | 6,258 | $12K | |
| Q9992 | Injection, buprenorphine extended-release (sublocade), greater than 100 mg | <1% | 38 | $12K |
| 77002 | <1% | 634 | $12K | |
| 96102 | <1% | 58 | $11K | |
| 82077 | <1% | 1,220 | $11K | |
| 90677 | <1% | 876 | $11K | |
| 99442 | <1% | 531 | $11K | |
| E0114 | Crutches underarm, other than wood, adjustable or fixed, pair, with pads, tips and handgrips | <1% | 598 | $11K |
| 96112 | <1% | 101 | $11K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,812 | $11K |
| 86592 | <1% | 944 | $11K | |
| 85730 | <1% | 2,644 | $11K | |
| 92002 | <1% | 364 | $11K | |
| 96417 | <1% | 166 | $11K | |
| 84480 | <1% | 957 | $10K | |
| 84146 | <1% | 681 | $10K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 510 | $10K |
| 97167 | <1% | 437 | $10K | |
| 86901 | <1% | 4,973 | $10K | |
| 73560 | <1% | 2,756 | $10K | |
| 73130 | <1% | 1,980 | $10K | |
| V2103 | Spherocylinder, single vision, plano to plus or minus 4.00d sphere, .12 to 2.00d cylinder, per lens | <1% | 249 | $10K |
| 88342 | <1% | 2,488 | $10K | |
| 20553 | <1% | 158 | $10K | |
| 64493 | <1% | 69 | $10K | |
| 95992 | <1% | 482 | $10K | |
| 87205 | <1% | 3,277 | $9K | |
| 83718 | <1% | 1,265 | $9K | |
| 90750 | <1% | 570 | $9K | |
| V2025 | Deluxe frame | <1% | 912 | $9K |
| 82746 | <1% | 923 | $9K | |
| 84703 | <1% | 926 | $9K | |
| 73140 | <1% | 1,393 | $9K | |
| 86618 | <1% | 481 | $9K | |
| 94729 | <1% | 2,787 | $9K | |
| 64400 | <1% | 48 | $9K | |
| 87493 | <1% | 351 | $9K | |
| 0064A | <1% | 564 | $8K | |
| 99243 | <1% | 152 | $8K | |
| 86039 | <1% | 1,011 | $8K | |
| 84156 | <1% | 2,877 | $8K | |
| 73564 | <1% | 1,026 | $8K | |
| 96121 | <1% | 143 | $8K | |
| 82977 | <1% | 1,390 | $8K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 99 | $8K |
| 83615 | <1% | 2,134 | $8K | |
| 76536 | <1% | 248 | $8K | |
| 0072A | <1% | 422 | $8K | |
| 31575 | <1% | 245 | $8K | |
| L4386 | Walking boot, non-pneumatic, with or without joints, with or without interface material, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | <1% | 567 | $7K |
| 90744 | <1% | 1,410 | $7K | |
| 99443 | <1% | 272 | $7K | |
| 92552 | <1% | 72 | $7K | |
| 20611 | <1% | 84 | $7K | |
| 90656 | <1% | 539 | $7K | |
| 90960 | End-stage renal disease related services monthly, for patients 20 years and older, with 4 or more face-to-face visits | <1% | 117 | $7K |
| J2426 | Injection, paliperidone palmitate extended release (invega sustenna), 1 mg | <1% | 47 | $7K |
| 0071A | <1% | 448 | $7K | |
| 86580 | <1% | 250 | $7K | |
| 36591 | <1% | 4,765 | $7K | |
| 92136 | <1% | 400 | $7K | |
| 87150 | <1% | 230 | $7K | |
| 95885 | <1% | 116 | $6K | |
| L4387 | Walking boot, non-pneumatic, with or without joints, with or without interface material, prefabricated, off-the-shelf | <1% | 275 | $6K |
| 82670 | <1% | 316 | $6K | |
| 99221 | <1% | 148 | $6K | |
| 90707 | <1% | 875 | $6K | |
| J0475 | Injection, baclofen, 10 mg | <1% | 28 | $6K |
| 90480 | <1% | 702 | $6K | |
| 82533 | <1% | 545 | $6K | |
| 84165 | <1% | 1,186 | $6K | |
| 72040 | <1% | 715 | $6K | |
| 99358 | Prolong nursin fac eval 15m | <1% | 200 | $6K |
| 90714 | <1% | 190 | $6K | |
| 96136 | <1% | 110 | $6K | |
| 83001 | <1% | 411 | $6K | |
| 86038 | <1% | 638 | $6K | |
| 80143 | <1% | 544 | $6K | |
| 80053 | Comprehensive metabolic panel | <1% | 481 | $6K |
| 96139 | <1% | 87 | $6K | |
| 90619 | <1% | 62 | $6K | |
| 90682 | <1% | 142 | $6K | |
| 86200 | <1% | 603 | $5K | |
| 80179 | <1% | 523 | $5K | |
| 64494 | <1% | 56 | $5K | |
| 87328 | <1% | 420 | $5K | |
| 58100 | <1% | 28 | $5K | |
| 97802 | <1% | 460 | $5K | |
| 85049 | <1% | 283 | $5K | |
| J7297 | Levonorgestrel-releasing intrauterine contraceptive system (liletta), 52 mg | <1% | 28 | $5K |
| 90687 | <1% | 94 | $5K | |
| 84550 | <1% | 1,851 | $5K | |
| 0124A | <1% | 428 | $5K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 93 | $5K |
| 72141 | <1% | 62 | $5K | |
| 64721 | <1% | 15 | $5K | |
| 96138 | <1% | 122 | $5K | |
| 11102 | <1% | 125 | $4K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 14 | $4K |
| 70486 | <1% | 148 | $4K | |
| 90662 | <1% | 1,464 | $4K | |
| 83883 | <1% | 759 | $4K | |
| 87625 | <1% | 155 | $4K | |
| 87045 | <1% | 239 | $4K | |
| 92250 | <1% | 716 | $4K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 13,310 | $4K |
| 83520 | <1% | 247 | $4K | |
| 92060 | <1% | 85 | $4K | |
| L3908 | Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf | <1% | 1,034 | $4K |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 397 | $4K |
| 86376 | <1% | 313 | $4K | |
| 86431 | <1% | 971 | $4K | |
| 86160 | <1% | 533 | $4K | |
| 86258 | <1% | 394 | $4K | |
| 90620 | <1% | 49 | $4K | |
| 84425 | <1% | 257 | $4K | |
| 87329 | <1% | 420 | $4K | |
| 29125 | <1% | 96 | $4K | |
| 94664 | <1% | 749 | $4K | |
| 88304 | <1% | 1,632 | $4K | |
| 0031A | <1% | 107 | $3K | |
| 51702 | <1% | 178 | $3K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 51 | $3K |
| 82140 | <1% | 426 | $3K | |
| 91300 | <1% | 3,486 | $3K | |
| 58300 | <1% | 61 | $3K | |
| 84163 | <1% | 75 | $3K | |
| 73590 | <1% | 364 | $3K | |
| 64635 | <1% | 27 | $3K | |
| 96131 | <1% | 38 | $3K | |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | <1% | 41 | $3K |
| 87468 | <1% | 127 | $3K | |
| 80197 | <1% | 180 | $3K | |
| 84155 | <1% | 1,450 | $3K | |
| 69209 | <1% | 104 | $3K | |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 45 | $3K |
| 90710 | <1% | 647 | $3K | |
| 97542 | <1% | 464 | $3K | |
| 77080 | <1% | 134 | $3K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 84 | $3K |
| 91319 | <1% | 90 | $3K | |
| 87529 | <1% | 79 | $3K | |
| 51798 | <1% | 1,277 | $3K | |
| 92341 | <1% | 110 | $3K | |
| 90672 | <1% | 32 | $3K | |
| 0012A | <1% | 98 | $3K | |
| 76820 | <1% | 196 | $3K | |
| 82248 | <1% | 819 | $3K | |
| 87536 | <1% | 40 | $3K | |
| 20550 | <1% | 29 | $3K | |
| 90697 | <1% | 531 | $3K | |
| 0134A | <1% | 235 | $3K | |
| 86255 | <1% | 235 | $3K | |
| 0011A | <1% | 98 | $3K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 1,463 | $2K |
| 99152 | <1% | 4,075 | $2K | |
| 43235 | <1% | 15 | $2K | |
| 36592 | <1% | 1,288 | $2K | |
| 20552 | <1% | 41 | $2K | |
| 73090 | <1% | 107 | $2K | |
| G0381 | Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 23 | $2K |
| 99495 | <1% | 80 | $2K | |
| 72170 | <1% | 262 | $2K | |
| L3807 | Wrist hand finger orthosis, without joint(s), prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | <1% | 112 | $2K |
| 88341 | <1% | 317 | $2K | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 27 | $2K |
| Q0139 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for esrd on dialysis) | <1% | 47 | $2K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 25,549 | $2K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 22,399 | $2K |
| 74019 | <1% | 740 | $2K | |
| 88142 | <1% | 121 | $2K | |
| 96137 | <1% | 49 | $2K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 41 | $2K |
| 76857 | <1% | 100 | $2K | |
| 96376 | <1% | 6,262 | $2K | |
| 95800 | <1% | 40 | $2K | |
| 76818 | <1% | 67 | $2K | |
| 87046 | <1% | 241 | $2K | |
| 69210 | <1% | 197 | $2K | |
| 98967 | <1% | 26 | $2K | |
| L1833 | Knee orthosis, adjustable knee joints (unicentric or polycentric), positional orthosis, rigid support, prefabricated, off-the shelf | <1% | 33 | $2K |
| 72158 | <1% | 16 | $2K | |
| 95910 | <1% | 40 | $2K | |
| 97032 | <1% | 239 | $2K | |
| 73080 | <1% | 151 | $2K | |
| 11100 | <1% | 67 | $2K | |
| 87075 | <1% | 204 | $1K | |
| 98968 | <1% | 29 | $1K | |
| 73552 | <1% | 183 | $1K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 297 | $1K |
| 0054A | <1% | 133 | $1K | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | <1% | 60 | $1K |
| 87220 | <1% | 198 | $1K | |
| 93294 | <1% | 114 | $1K | |
| 10061 | <1% | 13 | $1K | |
| 80177 | <1% | 35 | $1K | |
| 95908 | <1% | 60 | $1K | |
| 88141 | <1% | 70 | $1K | |
| 84704 | <1% | 75 | $1K | |
| 93922 | <1% | 103 | $1K | |
| 90961 | <1% | 25 | $1K | |
| 0081A | <1% | 69 | $1K | |
| 93295 | <1% | 48 | $1K | |
| 36430 | <1% | 14 | $1K | |
| 83993 | <1% | 66 | $1K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 15,053 | $1K |
| 62370 | <1% | 28 | $1K | |
| 86308 | <1% | 56 | $1K | |
| 86256 | <1% | 86 | $997.53 | |
| 11055 | <1% | 12 | $989.65 | |
| 95816 | <1% | 26 | $960.55 | |
| 90935 | Hemodialysis procedure with single evaluation by a physician | <1% | 32 | $931.61 |
| 92610 | <1% | 29 | $915.77 | |
| 99441 | <1% | 78 | $911.25 | |
| 99223 | Prolong inpt eval add15 m | <1% | 31 | $905.19 |
| 0082A | <1% | 29 | $890.84 | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 35 | $887.62 |
| L3260 | Surgical boot/shoe, each | <1% | 495 | $883.91 |
| 91318 | <1% | 71 | $874.92 | |
| 82951 | <1% | 12 | $828.37 | |
| 83002 | <1% | 60 | $825.42 | |
| 81015 | <1% | 235 | $807.18 | |
| 90723 | <1% | 210 | $806.58 | |
| 27096 | <1% | 12 | $804.40 | |
| 86481 | <1% | 14 | $802.38 | |
| 84590 | <1% | 104 | $801.51 | |
| 11056 | <1% | 15 | $796.60 | |
| 86334 | <1% | 80 | $763.17 | |
| 84402 | <1% | 39 | $761.84 | |
| 93880 | <1% | 14 | $761.60 | |
| 72156 | <1% | 17 | $757.80 | |
| 90746 | <1% | 19 | $737.27 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 23,467 | $733.12 |
| 90621 | <1% | 28 | $730.69 | |
| 93976 | <1% | 15 | $729.48 | |
| H0022 | Alcohol and/or drug intervention service (planned facilitation) | <1% | 46 | $727.20 |
| 76882 | <1% | 38 | $723.42 | |
| 73120 | <1% | 103 | $722.29 | |
| 73070 | <1% | 43 | $710.68 | |
| E2601 | General use wheelchair seat cushion, width less than 22 inches, any depth | <1% | 150 | $687.24 |
| 76813 | <1% | 14 | $663.18 | |
| 99451 | <1% | 26 | $662.21 | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 13 | $660.35 |
| 86709 | <1% | 74 | $658.01 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,164 | $644.39 |
| C7901 | Service for diagnosis, evaluation, or treatment of a mental health or substance use disorder, 30-60 minutes, provided remotely by hospital staff who are licensed to provided mental health services under applicable state law(s), when the patient is in their home, and there is no associated professional service | <1% | 225 | $602.83 |
| 92083 | <1% | 418 | $595.52 | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 45 | $570.69 |
| 91301 | <1% | 295 | $568.88 | |
| 82330 | <1% | 95 | $561.00 | |
| 80156 | <1% | 31 | $558.83 | |
| 82150 | <1% | 37 | $535.19 | |
| 83921 | <1% | 55 | $524.31 | |
| 66821 | <1% | 12 | $512.04 | |
| 96523 | <1% | 47 | $506.15 | |
| 93227 | <1% | 28 | $497.33 | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 13 | $496.28 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 6,124 | $496.12 |
| 0154A | <1% | 13 | $496.08 | |
| 93970 | <1% | 17 | $490.84 | |
| 64636 | <1% | 14 | $475.89 | |
| 83930 | <1% | 89 | $459.58 | |
| 99220 | <1% | 12 | $458.76 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 24,766 | $458.38 |
| 91306 | <1% | 299 | $435.17 | |
| 96381 | <1% | 51 | $408.72 | |
| 83986 | <1% | 27 | $392.83 | |
| 77334 | <1% | 15 | $372.13 | |
| 76000 | <1% | 61 | $365.94 | |
| 96380 | <1% | 35 | $357.63 | |
| 87338 | <1% | 30 | $353.48 | |
| 51701 | <1% | 93 | $351.06 | |
| 93225 | <1% | 26 | $320.12 | |
| 98941 | Chiropractic manipulative treatment; spinal, 3-4 regions | <1% | 22 | $308.48 |
| 86787 | <1% | 43 | $307.34 | |
| 84305 | <1% | 15 | $307.20 | |
| 90461 | <1% | 14 | $294.54 | |
| 76870 | <1% | 15 | $293.85 | |
| C1780 | Lens, intraocular (new technology) | <1% | 293 | $286.08 |
| 84478 | <1% | 71 | $284.87 | |
| 91303 | <1% | 101 | $284.86 | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 150 | $264.68 |
| L4350 | Ankle control orthosis, stirrup style, rigid, includes any type interface (e.g., pneumatic, gel), prefabricated, off-the-shelf | <1% | 60 | $259.19 |
| 86225 | <1% | 34 | $250.08 | |
| 93298 | <1% | 29 | $249.84 | |
| 84270 | <1% | 13 | $244.79 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,321 | $239.50 |
| 86147 | <1% | 26 | $238.86 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 20,452 | $238.36 |
| 91307 | <1% | 746 | $223.31 | |
| 73100 | <1% | 29 | $215.54 | |
| 80178 | <1% | 47 | $204.92 | |
| 99496 | <1% | 25 | $194.64 | |
| 93272 | <1% | 15 | $184.35 | |
| 85613 | <1% | 31 | $182.98 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 17,874 | $182.63 |
| 76937 | <1% | 47 | $179.53 | |
| 99406 | <1% | 30 | $177.03 | |
| 84630 | <1% | 19 | $173.13 | |
| 93244 | <1% | 12 | $171.41 | |
| 96132 | <1% | 14 | $168.24 | |
| 99217 | <1% | 13 | $166.96 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 1,837 | $164.98 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 33 | $164.87 |
| J3371 | Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg | <1% | 17 | $158.07 |
| 93016 | <1% | 12 | $157.50 | |
| J2704 | Injection, propofol, 10 mg | <1% | 29,454 | $152.44 |
| 99417 | Prolong home eval add 15m | <1% | 189 | $149.34 |
| 86146 | <1% | 15 | $143.42 | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 1,597 | $140.86 |
| 92133 | <1% | 393 | $137.77 | |
| 17000 | <1% | 26 | $131.67 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 1,777 | $128.58 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 2,377 | $125.58 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 4,441 | $115.05 |
| 93018 | <1% | 12 | $98.74 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 688 | $97.09 |
| L1832 | Knee orthosis, adjustable knee joints (unicentric or polycentric), positional orthosis, rigid support, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | <1% | 15 | $91.20 |
| G0008 | Administration of influenza virus vaccine | <1% | 2,702 | $90.75 |
| 90700 | <1% | 19 | $80.16 | |
| 88112 | <1% | 15 | $80.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 6,232 | $77.87 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,822 | $75.44 |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 572 | $73.78 |
| 91305 | <1% | 104 | $69.24 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 8,214 | $66.23 |
| J1815 | Injection, insulin, per 5 units | <1% | 5,960 | $62.62 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 19,634 | $58.04 |
| 0074A | <1% | 23 | $55.64 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 377 | $49.66 |
| 77001 | <1% | 28 | $49.28 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 1,962 | $48.53 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 13,557 | $43.47 |
| 87102 | <1% | 14 | $42.22 | |
| A9300 | Exercise equipment | <1% | 243 | $41.00 |
| 71101 | <1% | 35 | $40.74 | |
| 94618 | <1% | 12 | $39.90 | |
| A4649 | Surgical supply; miscellaneous | <1% | 5,651 | $35.79 |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | <1% | 1,016 | $35.49 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,266 | $33.98 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 4,622 | $33.06 |
| 91321 | <1% | 17 | $27.99 | |
| C1769 | Guide wire | <1% | 2,861 | $27.31 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 7,844 | $25.40 |
| J3490 | Unclassified drugs | <1% | 6,449 | $24.85 |
| 88312 | <1% | 14 | $24.10 | |
| 99418 | Prolong nursin fac eval 15m | <1% | 38 | $22.59 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,057 | $22.25 |
| 85048 | <1% | 16 | $20.60 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,831 | $20.46 |
| 73522 | <1% | 17 | $20.37 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,837 | $14.04 |
| 90739 | <1% | 13 | $11.96 | |
| 91313 | <1% | 45 | $8.66 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 202 | $7.60 |
| J1240 | Injection, dimenhydrinate, up to 50 mg | <1% | 1,352 | $7.42 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 401 | $7.20 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 736 | $6.68 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 4,700 | $6.68 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 55 | $5.28 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 2,682 | $5.18 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,130 | $4.28 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 10,995 | $3.26 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 836 | $2.98 |
| S0028 | Injection, famotidine, 20 mg | <1% | 882 | $2.93 |
| A6457 | Tubular dressing with or without elastic, any width, per linear yard | <1% | 270 | $2.06 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 3,474 | $1.69 |
| A9270 | Non-covered item or service | <1% | 2,694 | $1.24 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,350 | $0.67 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,928 | $0.40 |
| A4450 | Tape, non-waterproof, per 18 square inches | <1% | 105 | $0.24 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 488 | $0.01 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 47 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 546 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 477 | $0.00 |
| C1729 | Catheter, drainage | 0% | 1,207 | $0.00 |
| 91308 | 0% | 121 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 389 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 119 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 93 | $0.00 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 96 | $0.00 |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | 0% | 763 | $0.00 |
| C1776 | Joint device (implantable) | 0% | 19 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 606 | $0.00 |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | 0% | 790 | $0.00 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | 0% | 93 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 533 | $0.00 |
| A4358 | Urinary drainage bag, leg or abdomen, vinyl, with or without tube, with straps, each | 0% | 83 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 665 | $0.00 |
| 88173 | 0% | 33 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 144 | $0.00 |
| J1071 | Injection, testosterone cypionate, 1 mg | 0% | 197 | $0.00 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 0% | 122 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 42 | $0.00 |
| 91312 | 0% | 125 | $0.00 | |
| 99354 | 0% | 76 | $0.00 | |
| A4565 | Slings | 0% | 27 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 14 | $0.00 |
| 0034A | 0% | 15 | $0.00 | |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 15 | $0.00 |
| J3489 | Injection, zoledronic acid, 1 mg | 0% | 12 | $0.00 |
| 91311 | 0% | 13 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 14 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 343 | $0.00 |
| J2372 | Injection, phenylephrine hydrochloride (biorphen), 20 micrograms | 0% | 235 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 809 | $0.00 |
| J3535 | Drug administered through a metered dose inhaler | 0% | 391 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 201 | $0.00 |
| G0009 | Administration of pneumococcal vaccine | 0% | 444 | $0.00 |
| A4215 | Needle, sterile, any size, each | 0% | 2,338 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 68 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 1,099 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 79 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 182 | $0.00 |
| G8981 | Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 29 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 136 | $0.00 |
| A4648 | Tissue marker, implantable, any type, each | 0% | 134 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 208 | $0.00 |
| A4467 | Belt, strap, sleeve, garment, or covering, any type | 0% | 63 | $0.00 |
| J1836 | Injection, metronidazole, 10 mg | 0% | 38 | $0.00 |
| V2632 | Posterior chamber intraocular lens | 0% | 122 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 71 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 86 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 125 | $0.00 |
| J2373 | Injection, phenylephrine hydrochloride (immphentiv), 20 micrograms | 0% | 68 | $0.00 |
| 76377 | 0% | 105 | $0.00 | |
| V2784 | Lens, polycarbonate or equal, any index, per lens | 0% | 66 | $0.00 |
| J0687 | Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg | 0% | 105 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 316 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 143 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 15 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 66 | $0.00 |
| S0109 | Methadone, oral, 5 mg | 0% | 2,394 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 78 | $0.00 |
| G8982 | Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 41 | $0.00 |
| 20560 | 0% | 26 | $0.00 | |
| 91315 | 0% | 13 | $0.00 | |
| A6240 | Hydrocolloid dressing, wound filler, paste, sterile, per ounce | 0% | 15 | $0.00 |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 13 | $0.00 |
| 90381 | 0% | 12 | $0.00 | |
| 31231 | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialADANK, KARI (CCO)
| Provider | Location | Paid |
|---|---|---|
| Gundersen Clinic LTD | La Crosse, WI | $10.13M |
| Gundersen Lutheran Medical Center, INC. | La Crosse, WI | $1.96M |
| Gundersen Lutheran Medical Center INC | Onalaska, WI | $1.63M |
| Gundersen Clinic, LTD. | Lansing, IA | $379K |
| Gundersen Lutheran Medical Center INC | Viroqua, WI | $375K |
| Gundersen Lutheran Medical Center INC | Tomah, WI | $201K |
| Gundersen Lutheran Medical Center INC | Winona, MN | $89K |
| Gundersen Regional Clinics, LLC | Decorah, IA | $70K |
| Gundersen Lutheran Medical Center, INC | La Crosse, WI | $28K |
| Gundersen Clinic LTD | Spring Grove, MN | $2K |
| Gundersen Lutheran Medical Center, INC | Onalaska, WI | $2K |
| Gundersen Clinic, LTD. | Houston, MN | $977.31 |
| Gundersen Lutheran Medical Center, INC | La Crosse, WI | $827.41 |
| Gundersen Clinic LTD | Harmony, MN | $11.17 |
| Gundersen Lutheran Medical Center, INC. | La Crosse, WI | $0.00 |
| Gundersen Clinic, LTD. | Independence, WI | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.